GlassScriptPhysician profile
Manolis Thanasas
NPI 1558527812
$3,917.01
in general payments reported to CMS, 2019-2025
9 companies · $343 in 2025
The $343 reported for 2025 was more than what 86% of General Practice (Dentist) providers received nationally (typical 2025 total: $74.60).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $141 · 2020: $565 · 2021: $113 · 2022: $355 · 2023: $405 · 2024: $1,995 · 2025: $343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,598 · Food and Beverage: $931 · Education: $214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,598.13 |
| Food and Beverage | $931.11 |
| Education | $214.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimvie INC. | $2,005.49 | 2024-2025 | |
| Align Technology, INC. | $802.87 | 2019-2025 | Invisalign Go, Invisalign |
| Zimmer Biomet Holdings, INC. | $379.66 | 2019-2020 | |
| Hu-Friedy Mfg. Co., LLC | $249.05 | 2020-2025 | |
| Straumann USA LLC | $190.55 | 2022 | |
| Biolase, INC. | $137.21 | 2023 | Waterlase Iplus |
| Ultradent Products INC | $112.99 | 2021 | |
| Dentsply Sirona INC | $20.63 | 2025 | Cavitron |
| Orapharma, A Division of Bausch Health US, LLC | $18.56 | 2025 | Arestin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manolis Thanasas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.